SCHEMBL13028131

SCHEMBL13028131

CC(C)(C)OC(=O)N1CCN(c2ccncc2NC(=O)c2cccc(N3CCc4ccccc4C3=O)n2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHEK1 O14757 3/20 0.49
▸ BACE1 P56817 4/20 0.46
▸ PIM1 P11309 5/20 0.42
▸ PIM3 Q86V86 5/20 0.42
▸ PIM2 Q9P1W9 5/20 0.42
▸ PDE5A O76074 1/20 0.41
▸ PDE4A P27815 1/20 0.41
▸ PDE1A P54750 1/20 0.41
▸ PDE1B Q01064 1/20 0.41
▸ PDE4B Q07343 1/20 0.41
▸ PDE4C Q08493 1/20 0.41
▸ PDE4D Q08499 1/20 0.41
▸ PDE3B Q13370 1/20 0.41
▸ PDE1C Q14123 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ JAK2 O60674 1/20 0.40
▸ ROCK2 O75116 1/20 0.40
▸ IGF1R P08069 1/20 0.40
▸ MAPK1 P28482 1/20 0.40
▸ AKT1 P31749 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13028126 0.90 CHEK1 (0.48) CHEK1BACE1PIM1PIM3PIM2
SCHEMBL13028125 0.90 CHEK1 (0.53) CHEK1BACE1PIM2JAK2ROCK2
SCHEMBL13028130 0.89 CHEK1 (0.44) CHEK1BACE1PIM1PIM3PIM2
SCHEMBL13028136 0.87 BACE1 (0.48) CHEK1BACE1PIM1PIM3PIM2
SCHEMBL13028086 0.86 BACE1 (0.45) CHEK1BACE1PIM1PIM3PIM2
SCHEMBL13028132 0.86 BACE1 (0.46) CHEK1BACE1PIM1PIM3PIM2
SCHEMBL13028084 0.86 CHEK1 (0.46) CHEK1BACE1PIM1PIM3JAK2
SCHEMBL13028082 0.85 BACE1 (0.45) CHEK1BACE1PIM1PIM3PIM2
SCHEMBL13027452 0.85 CHEK1 (0.66) CHEK1PIM1PIM3PIM2JAK2
SCHEMBL13028074 0.84 CHEK1 (0.52) CHEK1BACE1PIM1PIM3PIM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293747-B2 Heterocyclic amide compounds as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-23 — — US disclosed
US-8293747-B2 Heterocyclic amide compounds as protein kinase inhibitors MERCK SHARP & DOHME CORP. (US) 2012-10-23 — — US disclosed
US-20100286135-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS Schering Corporation Patent Department, K-6-1; 1990 (US) 2010-11-11 — — US disclosed
US-20100286135-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS Schering Corporation Patent Department, K-6-1; 1990 (US) 2010-11-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286135-A1 HETEROCYCLIC AMIDE COMPOUNDS AS PROTEIN KINASE INHIBITORS MTOR, CDK1, MAP3K8 CHEK1 113/4885BACE1 550/4885PIM1 677/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback